Pre‐operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre‐operative radiotherapy and chemotherapy. The second scandinavian trial in esophageal cancer

Citations Over TimeTop 10% of 1992 papers

Abstract

In a prospective multicenter study, 186 patients with squamous cell esophageal carcinoma, who after evaluation were considered suitable for surgery, were randomized to 4 treatment groups: Group 1, surgery alone; Group 2, pre-operative chemotherapy (cisplatin and bleomycin) and surgery; Group 3, pre-operative irradiation (35 Gy) and surgery; Group 4, pre-operative chemotherapy, radiotherapy, and surgery. Three-year survival was significantly higher in the pooled groups receiving radiotherapy as compared with the pooled groups not receiving radiotherapy. Comparison of the groups having pre-operative chemotherapy with those not having chemotherapy showed no significant difference in survival. Female patients had a significantly better survival than males. The results indicate that pre-operative irradiation had a beneficial effect on intermediate term survival, whereas the chemotherapy regime used did not influence survival.

Related Papers

• → Genetic polymorphisms inTERTare associated with increased risk of esophageal cancer(2017)15 cited
• An Analysis of Esophageal Cancer Incidence and Mortality from 30 Cancer Registries in China,1998～2002(2007)
• → Long non-coding RNA LINC01617 promotes proliferation and metastasis of esophageal cancer cells through AKT pathway(2018)3 cited
• Study on the Changes of Serum Cytokine and Acute Phase Reaction Protein (APRP) in Patients with Esophageal Cancer and its Clinical Sinificance(2008)
• → Ethicon Travelling Fellowships (Cardiothoracic Surgery)(1983)